{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T15:08:20Z","timestamp":1770044900261,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Athens University"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.bcmd.2016.05.006","type":"journal-article","created":{"date-parts":[[2016,5,11]],"date-time":"2016-05-11T13:30:13Z","timestamp":1462973413000},"page":"100-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Assessment of serum bioactive hepcidin-25, soluble transferrin receptor and their ratio in predialysis patients: Correlation with the response to intravenous ferric carboxymaltose"],"prefix":"10.1016","volume":"59","author":[{"given":"Athina","family":"Drakou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Margeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stamatia","family":"Theodorakopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Agrogiannis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Poziopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Papassotiriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demetrios V.","family":"Vlahakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2016.05.006_bb0005","first-page":"S1","volume":"43","author":"National Kidney Foundation","year":"2004","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ki.1985.109","article-title":"Anemia of end-stage-renal-disease (ESRD)","volume":"28","author":"Eschbach","year":"1985","journal-title":"Kidney Int."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0015","first-page":"292","article-title":"Clinical practice guideline for anemia in chronic kidney disease","volume":"2","author":"Kidney Disease Improving Global Outcomes (KDIGO)","year":"2012","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0020","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.amjmed.2012.03.011","article-title":"Changing patterns of anemia management in US hemodialysis patients","volume":"125","author":"Freburger","year":"2012","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0025","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/ndt\/gfs580","article-title":"Red blood cell transfusion use in patients with chronic kidney disease","volume":"28","author":"Gill","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0030","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/ndt\/gft338","article-title":"Anaemia management in nondialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics","volume":"28","author":"Minutolo","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0035","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3201\/eid0503.990305","article-title":"Iron loading and disease surveillance","volume":"5","author":"Weinberg","year":"1999","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0040","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra041809","article-title":"Anemia of chronic disease","volume":"352","author":"Weiss","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0045","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/ajh.22108","article-title":"Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and sTfR\/log ferritin index","volume":"86","author":"Skikne","year":"2011","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0050","doi-asserted-by":"crossref","first-page":"7806","DOI":"10.1074\/jbc.M008922200","article-title":"Hepcidin, a urinary antimicrobial peptide synthesized in the liver","volume":"276","author":"Park","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0055","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0014-5793(00)01920-7","article-title":"LEAP-1, a novel highly disulfidebonded human peptide exhibits antimicrobial activity","volume":"480","author":"Krause","year":"2000","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0060","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1159\/000368512","article-title":"Iron status and inflammation in early stages of chronic kidney disease","volume":"40","author":"\u0141ukaszyk","year":"2015","journal-title":"Kidney Blood Press. Res."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0065","first-page":"1","article-title":"Iron, hepcidin and inflammatory status of young healthy overweight and obese women in Australia","volume":"8","author":"Cheng","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bcmd.2016.05.006_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0135227","article-title":"Plasma concentrations of hepcidin in anemic Zimbabwean infants","volume":"10","author":"Mupfudze","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bcmd.2016.05.006_bb0075","first-page":"504","article-title":"Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease","volume":"27","author":"Ashby","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0080","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/jcla.21634","article-title":"Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates","volume":"27","author":"Troutt","year":"2013","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0048250","article-title":"Increased serum hepcidin levels in subjects with the metabolic syndrome: a population study","volume":"7","author":"Martinelli","year":"2012","journal-title":"PloS ONE"},{"key":"10.1016\/j.bcmd.2016.05.006_bb0090","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0095","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1182\/blood-2015-03-636407","article-title":"Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia","volume":"125","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.05.006_bb0100","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2174\/1568026043451311","article-title":"Hematocrit lowering effect of renin angiotensin system with angiotensin converting enzyme inhibition and angiotensin receptor blockers","volume":"4","author":"Marathias","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0105","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/nu7010103","article-title":"Hepcidin-25, mean corpuscular volume, and ferritin as predictors of response to oral iron supplementation in hemodialysis patients","volume":"7","author":"Takasawa","year":"2015","journal-title":"Nutrients"},{"key":"10.1016\/j.bcmd.2016.05.006_bb0110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s40620-014-0083-y","article-title":"Serum hepcidin-25 and response to intravenous iron in patients with non-dialysis chronic kidney disease","volume":"28","author":"Chand","year":"2015","journal-title":"J. Nephrol."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0115","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1007\/s00134-010-1794-8","article-title":"Diagnostic accuracy of serum hepcidin for iron deficiency in critically ill patients with anemia","volume":"36","author":"Lasocki","year":"2010","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0120","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1093\/ndt\/gfq321","article-title":"Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents","volume":"25","author":"Tessitore","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0125","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1182\/blood-2004-12-4844","article-title":"Hepcidin in iron overload disorders","volume":"105","author":"Papanikolaou","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.05.006_bb0130","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/rheumatology\/33.8.740","article-title":"Is serum transferrin receptor useful for detecting iron deficiency inn anemic patients with chronic inflammatory disease?","volume":"33","author":"Petterson","year":"1994","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0135","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1081\/JDI-100104737","article-title":"C reactive protein in patients with chronic renal diseases","volume":"23","author":"Panichi","year":"2001","journal-title":"Ren. Fail."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0140","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1128\/IAI.00983-13","article-title":"Hepcidin induction by pathogens and pathogen-derived molecules is strongly dependent on interleukin-6","volume":"82","author":"Rodriguez","year":"2014","journal-title":"Infect. Immun."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0145","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1182\/blood-2002-10-3235","article-title":"Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein","volume":"101","author":"Nemeth","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.05.006_bb0150","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1182\/blood-2005-03-1159","article-title":"Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS","volume":"106","author":"Kemna","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.05.006_bb0155","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1182\/blood-2011-01-258467","article-title":"Hepcidin and iron regulation, 10years later","volume":"117","author":"Ganz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.05.006_bb0160","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/ki.2009.21","article-title":"Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease","volume":"75","author":"Ashby","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0165","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1093\/ndt\/gfm316","volume":"22","author":"Artunc","year":"2007","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.bcmd.2016.05.006_bb0170","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2015-07-658419","article-title":"Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of \u03b2-thalassemia","volume":"126","author":"Kautz","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bcmd.2016.05.006_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151601","article-title":"Associations among erythroferrone and biomarkers of erythropoiesis and iron metabolism, and treatment with long-term erythropoiesis-stimulating agents in patients on hemodialysis","volume":"11","author":"Honda","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcmd.2016.05.006_bb0180","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1586\/14789450.2015.1099436","article-title":"Plasma hepcidin in early-stage breast cancer patients: no relationship with interleukin-6, erythropoietin and erythroferrone","volume":"12","author":"Ciniselli","year":"2015","journal-title":"Expert Rev. Proteomics"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616300547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616300547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:32:14Z","timestamp":1761049934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979616300547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":36,"alternative-id":["S1079979616300547"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.05.006","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of serum bioactive hepcidin-25, soluble transferrin receptor and their ratio in predialysis patients: Correlation with the response to intravenous ferric carboxymaltose","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}